IONS - アイオニス・ファ―マシュ―ティカルズ （Ionis Pharmaceuticals Inc.） アイオニス・ファ―マシュ―ティカルズIONSのチャート
IONSの企業情報
| symbol | IONS |
|---|---|
| 会社名 | Ionis Pharmaceuticals Inc （アイオニス・ファ―マシュ―ティカルズ） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 イオニス・ファーマシューティカルズ（Ionis Pharmaceuticals Inc.）（旧名：Isis Pharmaceuticals Inc.）はリボ核酸標的（RNA標的）薬の発見・開発会社である。同社はアンチセンス薬の発見・開発に焦点を当てる。同社のアンチセンス薬は、心血管、代謝、神経疾患を含む重症・希少疾患、及び癌等疾患の治療に使用される。Volanesorsenは、家族制カイロミクロン血症(FCS)と呼ばれる遺伝子疾患を持つ患者及び限局性脂肪異栄養症を持つ患者を含む高トリグリセリドレベルを有する患者の治療のための薬である。同社は、後期フェーズIII薬、nusinersen、volanesorsenとIONIS-TTRを市場に導入することに焦点を当てる。同社の脂質低下製品KYNAMRO（ミポメルセンナトリウム）注射液は、米国市場でホモ接合型家族性高コレステロール血症（HoFH）を持つ患者に使用される。同社の製品はまたAlicaforsen、IONIS-DMPK-2.5、PlazomicinとIONIS-GCGRが含まれる。 アイオニス・ファ―マシュ―ティカルズは米国のバイオ医薬品企業。主に治療用新化合物の発見・製造・販売に従事。同社製品には遺伝性高脂血症治療薬の｢KYNAMRO｣や、高トリグリセリド血症治療薬の｢ISIS-APOCIIIRx｣や｢ISIS-FXIRx｣がある。本社はカリフォルニア州サンディエゴ。 For more than 30 years, Ionis has been the leader in RNA-targeted therapy, pioneering new markets and changing standards of care with its novel antisense technology. Ionis currently has three marketed medicines and a premier late-stage pipeline highlighted by industry-leading neurological and cardiometabolic franchises. Its scientific innovation began and continues with the knowledge that sick people depend on it, which fuels its vision of becoming one of the most successful biotechnology companies. |
| 本社所在地 | 2855 Gazelle Court Carlsbad CA 92010 USA |
| 代表者氏名 | Stanley T. Crooke スタンリーT.クルーク |
| 代表者役職名 | Chairman of the Board President Chief Executive Officer 取締役会長兼最高経営責任者（CEO） |
| 電話番号 | +1 760-931-9200 |
| 設立年月日 | 32509 |
| 市場名 | NASDAQ National Market System |
| ipoyear | ―年 |
| 従業員数 | 547人 |
| url | www.ionispharma.com |
| nasdaq_url | https://www.nasdaq.com/symbol/ions |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -32.05600 |
| 終値（lastsale） | 44.96 |
| 時価総額（marketcap） | 6171834858.72 |
| 時価総額 | 時価総額（百万ドル） 6203.408 |
| 売上高 | 売上高（百万ドル） 555.37600 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 4848.796 |
| 当期純利益 | 当期純利益（百万ドル） 67.31500 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Ionis Pharmaceuticals Inc revenues increased 19% to $262.2M. Net loss increased from $2.2M to $41.8M. Revenues reflect Akcea Therapeutics segment increase from $11.8M to $35.4M. Higher net loss reflects Ionis core segment income decrease of 63% to $40.5M Akcea Therapeutics segment loss increase of 13% to $93.8M Elimination of Intercompany Activity segment loss totaling $379K vs. income of $60K. |
IONSのテクニカル分析
IONSのニュース
RXDX vs. IONS: Which Biotech Stock is Better? 2023/03/02 19:46:14 TipRanks
In this piece, I evaluated two biotech stocks, Prometheus Biosciences (NASDAQ:RXDX) and Ionis Pharmaceuticals (NASDAQ:IONS), to determine which is …
Ionis Pharmaceuticals PT Lowered to $61 at Piper Sandler 2023/02/23 11:19:21 Investing.com
https://www.investing.com/news/pro/ionis-pharmaceuticals-pt-lowered-to-61-at-piper-sandler-432SI-3011820
Ionis Pharmaceuticals PT Lowered to $30 at Citi 2023/02/23 08:57:23 Investing.com
https://www.investing.com/news/pro/ionis-pharmaceuticals-pt-lowered-to-30-at-citi-432SI-3011608
Ionis Pharmaceuticals, Inc. (IONS) Q4 2022 Earnings Call Transcript 2023/02/22 19:57:05 Seeking Alpha
Ionis Pharmaceuticals, Inc. (NASDAQ:NASDAQ:IONS) Q4 2022 Results Conference Call February 22, 2023 11:30 AM ETCompany ParticipantsWade Walke - SVP, IRBrett Monia - CEOBeth Hougen -…
Ionis Pharmaceuticals: Q4 Earnings Snapshot 2023/02/22 12:27:38 WTOP
CARLSBAD, Calif. (AP) — CARLSBAD, Calif. (AP) — Ionis Pharmaceuticals Inc. (IONS) on Wednesday reported a fourth-quarter loss of $52…
Astrazeneca PLC – Consensus Indicates Potential 21.5% Upside 2023/02/06 11:21:17 DirectorsTalk
Astrazeneca PLC found using ticker (AZN) have now 7 analysts in total covering the stock. The consensus rating is ''Buy''. The target price ranges between 88 and 65 and has a mean target at 76.71. With the stocks previous close at 63.15 this would indicate that there is a potential upside of 21.5%. The day 50 moving average is 68.11 and the 200 day moving average is 64.1. The company has a market cap of $202,272m. You can visit the company''s website by visiting: https://www.astrazeneca.com The potential market cap would be $245,705m based on the market concensus. AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases.
Ionis granted FDA fast track status for dyslipidemia candidate 2023/01/31 12:53:23 Seeking Alpha
Ionis Pharmaceuticals (IONS) announced Tuesday that the FDA issued Fast Track designation for its investigational therapy olezarsen for a rare form of dyslipidemia. Read the full story here.
Ionis Pharmaceuticals Inc. (IONS) did well last session? 2023/01/27 16:40:00 US Post News
In Thursday’s session, Ionis Pharmaceuticals Inc. (NASDAQ:IONS) marked $39.38 per share, down from $39.75 in the previous session. While Ionis Pharmaceuticals Inc. has underperformed by -0.93%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, IONS rose by 25.10%, with highs and lows ranging from $48.82 to […]
Biogen, Ionis ALS therapy set for March FDA AdCom meeting (NASDAQ:BIIB) 2023/01/23 14:29:37 Seeking Alpha
The FDA announced that a panel of experts is scheduled to discuss the approval for tofersen an ALS therapy Biogen (BIIB) and Ionis Pharma (IONS) has developed. Read the full story here.
Ionis Pharmaceuticals PT Raised to $62 at Piper Sandler 2023/01/19 11:37:08 Investing.com
https://www.investing.com/news/pro/ionis-pharmaceuticals-pt-raised-to-62-at-piper-sandler-432SI-2983700
Is It Safe To Invest In Ionis Pharmaceuticals Inc. (NASDAQ: IONS) Now? 2022/12/24 12:00:00 Stocks Register
Ionis Pharmaceuticals Inc. (NASDAQ:IONS) price on Friday, December 23, fall -1.47% below its previous day’s close as a downside momentum from buyers pushed the stock’s value to $38.16. A look at the stock’s price movement, the close in the last trading session was $38.73, moving within a range at $37.69 and $38.525. The beta value … Is It Safe To Invest In Ionis Pharmaceuticals Inc. (NASDAQ: IONS) Now? Read More »
Ionis Pharmaceuticals begun at equalweight at Morgan Stanley on eplontersen launch 2022/12/21 18:47:31 Seeking Alpha
Morgan Stanley has initiated Ionis Pharmaceuticals (IONS) with an equalweight rating saying it expects a competitive launch for eplontersen next year and pipeline data wont come until 2024.
Morgan Stanley Downgrades Ionis Pharmaceuticals to Equalweight 2022/12/21 06:11:01 Investing.com
https://www.investing.com/news/pro/morgan-stanley-downgrades-ionis-pharmaceuticals-to-equalweight-432SI-2968282
Astrazeneca PLC – Consensus Indicates Potential 8.3% Upside 2022/12/19 12:56:55 DirectorsTalk
Astrazeneca PLC found using ticker (AZN) have now 5 analysts covering the stock. The analyst consensus points to a rating of ''Buy''. The target price ranges between 88 and 64.5 and has a mean target at 75.5. Given that the stocks previous close was at 69.74 this indicates there is a potential upside of 8.3%. The day 50 moving average is 62.31 and the 200 day MA is 63.59. The company has a market cap of $218,593m. Find out more information at: https://www.astrazeneca.com [stock_market_widget type="chart" template="basic" color="green" assets="AZN" range="6mo" interval="1d" axes="true" cursor="true" api="yf"] The potential market cap would be $236,647m based on the market concensus. AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases.
Ionis Pharmaceuticals Earnings Perspective: Return On Capital Employed 2022/12/13 14:48:36 Benzinga
According to data from Benzinga Pro, during Q3, Ionis Pharmaceuticals ''s (NASDAQ: IONS ) reported sales totaled $160.00 million. Despite a 55.3% increase in earnings, the company posted a loss of $46.99 million. Ionis Pharmaceuticals collected $134.00 million in revenue during Q2, but reported earnings showed a $105.14 million loss. Why Is ROCE Significant? Return on Capital Employed is a measure of yearly pre-tax profit relative to capital employed by a business. Changes in earnings and sales indicate shifts in a company''s ROCE. A higher ROCE is generally representative of successful growth of a company and is … Full story available on Benzinga.com